The Quantellect read.As of Nov 19, 2026, 13 active firms cover Bio-Techne Corp: 2 rate it Buy or better, 11 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $50.00 to $79.00, a moderate spread. The average target of $69.55 sits 4% below the current $72.74. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.55 next quarter toward $2.31 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 active firms
Neutral
Strong Buy00%
Buy215%
Neutral1185%
Sell00%
Strong Sell00%
Based on 13 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$69.55
-4.4% downside
Average target across 11 active firms as of Nov 19, 2026 vs $72.74 current
Highest Target$79.00
Average Target$69.55
Lowest Target$50.00
Detailed analyst forecasts for TECH
Showing 1–13 of 13 named analysts shown · 13 active firms in the rating projection
As of Nov 19, 2026, 2 of 13 active firms rate TECH a Buy (11 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TECH EPS & revenue forecast
EPS · NEXT QUARTER
$0.55
Range $0.52 – $0.57 · 6 analysts · +4% YoY
Next period, 6 analysts expect Bio-Techne Corp to earn $0.55 a share (range $0.52 – $0.57), versus $0.53 a year earlier. Full-year consensus is $2.01, growing to $2.31 the year after.
REVENUE · NEXT QUARTER
$327.2M
Range $323.3M – $330.0M · 6 analysts · +5% YoY
Revenue is expected to reach $327.2M (range $323.3M – $330.0M), +5.1% year-over-year. Full-year consensus is $1.3B, rising to $1.4B next year.
Top analysts covering Bio-Techne Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TECH.
#1
Puneet Souda
Leerink Partners · Rank #30
Neutral
$73.00+0.4% to target
Overall win rate
57%
+ Follow
#2
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$75.00+3.1% to target
Overall win rate
47%
+ Follow
#3
Conor McNamara
RBC Capital · Rank #254
Buy
$73.00+0.4% to target
Overall win rate
34%
+ Follow
#4
David Westenberg
Piper Sandler · Rank #314
Neutral
$65.00-10.6% to target
Overall win rate
35%
+ Follow
#5
RW
Robert Wasserman
Benchmark · Rank #388
Neutral
No targeton TECH
Overall win rate
41%
+ Follow
TECH stock forecast FAQ
What is TECH's average 12-month price target?+
The 11 active firms with a live target average $69.55 for Bio-Techne Corp over the next 12 months, ranging from a $79.00 high to a $50.00 low, as of Nov 19, 2026.
Is TECH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 13 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 11 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TECH?+
The Street-high target is $79.00 (UBS), and the Street-low is $50.00 (Evercore ISI Group). The average of all 11 active-firm targets is $69.55.
How many active Wall Street firms cover TECH?+
13 active firms have a recognized rating on Bio-Techne Corp as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TECH?+
Among analysts who currently cover TECH, Puneet Souda of Leerink Partners has the strongest overall Quantellect track record (Rank #30). Their current call is Neutral with a $73.00 target.
What is Bio-Techne Corp's projected EPS for next quarter?+
The consensus estimate is $0.55 per share (range $0.52 – $0.57) across 6 analysts. Full-year EPS is projected at $2.01, rising to $2.31 the following year.
How much revenue is Bio-Techne Corp expected to report next quarter?+
Consensus revenue is $327.2M (range $323.3M – $330.0M). Full-year revenue is projected at $1.3B, growing to $1.4B next year.
Have analysts been upgrading or downgrading TECH lately?+
As of Nov 19, 2026, 2 of 13 active firms rate TECH a Buy (11 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TECH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.